This study evaluated COVID-19 course and outcomes in multiple sclerosis (MS) patients treated with ocrelizumab (OCR), fingolimod (FNG), or natalizumab (NTZ) after a third mRNA vaccine dose. 290 patients from 17 Italian MS centers were included. While those on OCR and FNG showed slightly more symptomatic COVID-19 and higher hospitalization rates than those on NTZ, regression models indicated that most differences weren't due to DMTs. No deaths occurred. The study supports the third booster dose's effectiveness against severe COVID-19 in MS patients on OCR and FNG.
Publisher
Multiple Sclerosis Journal
Published On
Mar 29, 2023
Authors
Rocco Capuano, Luca Prosperini, Manuela Altieri, Lorena Lorefice, Roberta Fantozzi, Paola Cavalla, Clara Guaschino, Marta Radaelli, Cinzia Cordioli, Viviana Nociti, Laura Boffa, Paolo Ragonese, Maria Di Gregorio, Federica Pinardi, Valentina Torri Clerici, Giovanna De Luca, Alberto Gajofatto, Damiano Paolicelli, Carla Tortorella, Claudio Gasperini, Claudio Solaro, Eleonora Cocco, Alvino Bisecco, Antonio Gallo, Giovanni Di Dio
Tags
COVID-19
multiple sclerosis
ocrelizumab
fingolimod
natalizumab
vaccine effectiveness
hospitalization rates
Related Publications
Explore these studies to deepen your understanding of the subject.
